June 26, 2024
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the proposed merger between the below listed companies.  Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of the company being acquired.  

Kuehn Law is investigating whether the Board of Directors of the target company:

1) acted to maximize shareholder value,
2) failed to disclose material information, and
3) conducted a fair process:  
Alimera Sciences, Inc. has agreed to sell to ANI Pharmaceuticals, Inc. for $5.50 per share in cash at closing, plus a non-tradable contingent value right for up to $0.50 per share if specific net revenue targets are met in 2026 and 2027.